论文部分内容阅读
目的探讨肺炎支原体(MP)肺炎患儿肺功能的变化及不同治疗措施对肺功能的影响。方法选择2007年3月-2008年7月在本院住院治疗的90例MP肺炎患儿作为观察组,同时选择年龄、性别与观察组相匹配的45例健康儿童为健康对照组。分别采用儿童肺功能仪测定2组儿童肺功能指标,并将90例MP肺炎患儿随机分为观察1组和观察2组(各45例),分别予不同治疗措施。观察1组单纯用阿奇霉素针剂10mg/(kg.d),加50g/L葡萄糖注射液100mL,1次/d,连用3～5d;症状控制后改为口服阿奇霉素10mg/(kg.d),1次/d,连用3d,停药4d,疗程3周。观察2组在观察1组的基础上加用孟鲁司特钠治疗3周,治疗前后作肺功能检测,并随访6个月。结果观察组患儿肺功能呈现呼吸道阻塞的改变,治疗后肺功能较治疗前明显改善;观察2组总有效率(97.78%)与观察1组(95.56%)比较,差异无统计学意义(P>0.05),观察2组病程[(7.27±1.44)d]较观察1组病程[(12.11±2.24)d]明显缩短(P<0.05)。观察组治疗前后肝肾功能比较无明显差异(P>0.05)。结论肺功能检测对小儿MP肺炎治疗效果的评价有着重要的作用;孟鲁司特钠佐治MP肺炎能缩短病程,减少病情反复次数,改善小呼吸道功能。
Objective To investigate the changes of pulmonary function in children with Mycoplasma pneumoniae (MP) pneumonia and the effects of different treatment on pulmonary function. Methods Ninety children with MP pneumonia hospitalized in our hospital from March 2007 to July 2008 were selected as the observation group and 45 healthy children whose age and gender matched the observation group were selected as the healthy control group. Two sets of children’s pulmonary function indexes were determined by using children’s pulmonary function test instrument. Ninety children with MP pneumonia were randomly divided into observation group 1 and observation group 2 (each 45 cases), and were given different treatment measures respectively. The patients in group 1 were treated with azithromycin 10 mg / (kg · d) only, plus 50 g / L glucose injection 100 mL once daily for 3 ~ 5 days. The symptoms were changed to oral azithromycin 10 mg / (kg · d), 1 Times / d, even with 3d, withdrawal 4d, treatment for 3 weeks. The observation group 2 was treated with montelukast sodium for 3 weeks on the basis of the observation group 1, and the pulmonary function tests were performed before and after the treatment and were followed up for 6 months. Results The lung function of the observation group showed changes of airway obstruction. The lung function of the observation group was significantly improved after treatment. The total effective rate (97.78%) in the observation group was not significantly different from that in the observation group 1 (95.56%) (P > 0.05). The course of the disease in the two groups ([7.27 ± 1.44] d] was significantly shorter than that in the observation group [(12.11 ± 2.24) d] (P <0.05). The observation group had no significant difference in liver and kidney function before and after treatment (P> 0.05). Conclusion Pulmonary function tests play an important role in the evaluation of the therapeutic effect of MP pneumonia in children. Montelukast sodium MP pneumonia can shorten the course of the disease, reduce the frequency of repeated illness and improve the function of small airway.